Skip to content
DataLookout
Menu

NCT07683104

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 84 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date changed from estimate of Nov 18, 2026 to Nov 10, 2026
  2. Minor Start date: Nov 17, 2026 to Nov 18, 2026
  3. Minor Start date: Nov 15, 2026 to Nov 17, 2026
  4. Minor Start date: Nov 12, 2026 to Nov 15, 2026
  5. Minor Start date: Nov 11, 2026 to Nov 12, 2026
Show 45 earlier versionsHide 45 earlier versions
  1. Minor Start date: Nov 10, 2026 to Nov 11, 2026
  2. Minor Start date: Nov 9, 2026 to Nov 10, 2026
  3. Minor Start date: Nov 8, 2026 to Nov 9, 2026
  4. Minor Start date: Nov 5, 2026 to Nov 8, 2026
  5. Minor Start date: Nov 4, 2026 to Nov 5, 2026
  6. Minor Start date: Nov 3, 2026 to Nov 4, 2026
  7. Minor Start date: Nov 2, 2026 to Nov 3, 2026
  8. Minor Start date: Nov 1, 2026 to Nov 2, 2026
  9. Minor Start date: Oct 29, 2026 to Nov 1, 2026
  10. Minor Start date: Oct 28, 2026 to Oct 29, 2026
  11. Minor Start date: Oct 27, 2026 to Oct 28, 2026
  12. Minor Start date: Oct 26, 2026 to Oct 27, 2026
  13. Minor Start date: Oct 25, 2026 to Oct 26, 2026
  14. Minor Start date: Oct 22, 2026 to Oct 25, 2026
  15. Minor Start date: Oct 21, 2026 to Oct 22, 2026
  16. Minor Start date: Oct 20, 2026 to Oct 21, 2026
  17. Minor Start date: Oct 19, 2026 to Oct 20, 2026
  18. Minor Start date: Oct 18, 2026 to Oct 19, 2026
  19. Minor Start date: Oct 14, 2026 to Oct 18, 2026
  20. Minor Start date: Oct 13, 2026 to Oct 14, 2026
  21. Minor Start date: Oct 12, 2026 to Oct 13, 2026
  22. Minor Start date: Oct 11, 2026 to Oct 12, 2026
  23. Minor Start date: Oct 8, 2026 to Oct 11, 2026
  24. Minor Start date: Oct 7, 2026 to Oct 8, 2026
  25. Minor Start date: Oct 6, 2026 to Oct 7, 2026
  26. Minor Start date: Oct 5, 2026 to Oct 6, 2026
  27. Minor Start date: Oct 4, 2026 to Oct 5, 2026
  28. Minor Start date: Sep 20, 2026 to Oct 4, 2026
  29. Minor Start date: Sep 17, 2026 to Sep 20, 2026v51
  30. Minor Start date: Sep 16, 2026 to Sep 17, 2026v50
  31. Minor Start date: Sep 15, 2026 to Sep 16, 2026v49
  32. Minor Start date: Sep 14, 2026 to Sep 15, 2026v48
  33. Minor Start date: Sep 10, 2026 to Sep 14, 2026v47
  34. Minor Start date: Sep 9, 2026 to Sep 10, 2026v46
  35. Minor Start date: Sep 8, 2026 to Sep 9, 2026v45
  36. Minor Start date: Sep 7, 2026 to Sep 8, 2026v44
  37. Minor Start date: Sep 6, 2026 to Sep 7, 2026v43
  38. Minor Start date: Sep 3, 2026 to Sep 6, 2026v42
  39. Minor Start date: Sep 2, 2026 to Sep 3, 2026v41
  40. Minor Start date: Sep 1, 2026 to Sep 2, 2026v40
  41. Minor Start date: Aug 31, 2026 to Sep 1, 2026v39
  42. Minor Start date: Aug 30, 2026 to Aug 31, 2026v38
  43. Minor Start date: Aug 27, 2026 to Aug 30, 2026v37
  44. Minor Start date: Aug 26, 2026 to Aug 27, 2026v36
  45. Minor Start date: Aug 25, 2026 to Aug 26, 2026v35
  • Minor: routine updates

Endpoints

Primary

Clinical characterization of participants with trisomy 8 mosaicism and related disorders based on history, physical examination, radiologic imaging, and laboratory testing.
Timeframe: Length of the study
Characterization of immunologic profile of participants with trisomy 8 mosaicism and related disorders over time in comparison to healthy controls using cellular and molecular techniques
Timeframe: Length of the study

Secondary (4)

Characterization of laboratory, radiologic examinations, biopsies, and physical exam findings.
Identification of individuals with trisomy 8 who develop malignancy and assessment of risk factors including but not limited to history, findings on bone marrow biopsies and CBCs, NGS for risk variants, and flow cytometry.
Determination of the percentage of trisomy 8 cells in various tissue types including bone marrow, blood, fibroblasts cultured from skin, and biopsy samples, and the association with clinical phenotype.
Assessment of treatment response based on inflammatory markers, clinical history, and physical exam findings.

Arms and interventions

Affected Participants

Individuals ages \<= 99 with known or suspected trisomy 8 mosaicism, or with clinical phenotype consisting of mucosal ulcerations similar to TRIAD.

Non-affected biological family member participants

Non-affected biological family members of enrolled participants.

Sites

1 site in 1 country

  • National Institutes of Health Clinical CenterBethesda, Maryland, United States